Literature DB >> 1702907

HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T cells.

H Watanabe1, M Okumura, K Hirayama, T Sasazuki.   

Abstract

We have previously reported that in nonresponders to hepatitis-B (HB) vaccine there was an HLA-linked immune suppression gene for hepatitis-B surface antigen (Is-HBsAg) controlling the nonresponsiveness to HBsAg, through HBsAg-specific suppressor T cells, and that the Is-HBsAg was in strong linkage disequilibrium with the HLA-Bw54-DR4-DRw53 haplotype (1). We have now done the HLA typing on an additional 6 nonresponders, and using the system of T-cell proliferative response to HBsAg we found that the Is-HBsAg controlled the nonresponsiveness to HBsAg through HBsAg-specific suppressor T cells in nonresponders to HB vaccine who have HLA-Bw54-DR4-DRw53-DQw4 haplotype. T- and B-cell recognition of HB vaccines might play an important role at 3 to 5 weeks after the last immunization. Use of an anti-HLA monoclonal antibody has shown that the HLA-DR molecule plays an important role in helper T-cell proliferation in nonresponders, although the role of HLA-DQ molecule in nonresponders was unclear.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702907     DOI: 10.1111/j.1399-0039.1990.tb01802.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  13 in total

1.  Allele-specific expression of the cytoplasmic exon of HLA-DQB1 gene.

Authors:  S Senju; A Kimura; M Yasunami; N Kamikawaji; H Yoshizumi; Y Nishimura; T Sasazuki
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

2.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines.

Authors:  Vijayakumar Velu; Shanmugam Saravanan; Subhadra Nandakumar; Esaki-Muthu Shankar; Appasamy Vengatesan; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

3.  T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals.

Authors:  Martin R Weihrauch; Michael von Bergwelt-Baildon; Milos Kandic; Martin Weskott; Winfried Klamp; Joachim Rosler; Joachim L Schultze
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 4.  Searching for the human genetic factors standing in the way of universally effective vaccines.

Authors:  Alexander J Mentzer; Daniel O'Connor; Andrew J Pollard; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

Review 5.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

6.  Normal HBsAg presentation and T-cell defect in the immune response of nonresponders.

Authors:  M Salazar; H Deulofeut; C Granja; R Deulofeut; D E Yunis; D Marcus-Bagley; Z Awdeh; C A Alper; E J Yunis
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

7.  Hepatitis B surface antigen presentation and HLA-DRB1*- lessons from twins and peptide binding studies.

Authors:  A Kruger; P Adams; J Hammer; W O Böcher; P M Schneider; C Rittner; T Hoehler
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

8.  Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen.

Authors:  M A Shokrgozar; F Shokri
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

9.  Variable response to a candidate cancer vaccine antigen: MHC control of the antibody response in the rat to avian erythroblastosis virus (AEV)-encoded epithelial growth factor receptor but not AEV-encoded thyroid hormones receptor.

Authors:  N Nardi; N A Mitchison
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

10.  Large granular lymphocyte expansions in patients with Felty's syndrome: analysis using anti-T cell receptor V beta-specific monoclonal antibodies.

Authors:  S J Bowman; M Bhavnani; G C Geddes; V Corrigall; A W Boylston; G S Panayi; J S Lanchbury
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.